Acumen Pharmaceuticals (ABOS) Total Debt (2025 - 2026)
Acumen Pharmaceuticals recorded quarterly Total Debt of $14.1 million in Q1 2026, up 61.13% quarter-over-quarter from $8.8 million in Q4 2025.
Acumen Pharmaceuticals' Total Debt history runs 2 years deep, the most recent figure standing at $14.1 million for Q1 2026.
- In Q1 2026, Total Debt changed N/A year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (changed N/A YoY), while the FY2025 annual figure was $8.8 million, changed N/A from the prior year.
- Total Debt came in at $14.1 million for Q1 2026 at Acumen Pharmaceuticals, up from $8.8 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $14.1 million in Q1 2026 to a low of $3.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | 14.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.12 Mn |
| Dec 31, 2025 | 8.77 Mn |
| Sep 30, 2025 | 3.60 Mn |